CTLA4 and Pruritus: RRs for pruritus and rash developed after PD-1/-L1 inhibitor were decreased compared to CTLA-4 inhibitor, which is in line with the current mainstream consensus that CTLA-4 inhibitor is more likely to lead to pruritus and rash (Almutairi et al., 2020; Geisler et al., 2020; Hansen et al., 2017; Sibaud et al., 2016).